Company news

InflaRx N.V. news in 2023

InflaRx N.V.'s news releases, calls and decks from 2023, newest first.

View company

InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum

November 5, 2023

InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update

October 31, 2023

InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904

September 10, 2023

InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)

August 29, 2023

InflaRx Reports Second Quarter 2023 Financial Results & Operating Update

August 9, 2023

InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer

June 27, 2023

InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients

June 20, 2023

InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business Update

May 10, 2023

InflaRx Announces Closing of the Full Exercise of Greenshoe Option Increasing the Proceeds of the Recently Announced Public Offering of Ordinary Shares to US$46 million

April 17, 2023

InflaRx Announces Closing of $40 Million Public Offering of Ordinary Shares

April 13, 2023

InflaRx Announces Pricing of $40 Million Public Offering of Ordinary Shares

April 11, 2023

InflaRx Announces Public Offering of Ordinary Shares

April 10, 2023

InflaRx Reports Full Year 2022 Financial and Operating Results

March 21, 2023

InflaRx Provides Update on Planned Phase III Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of its EUA Application in Critically Ill COVID-19 Patients

January 4, 2023

Decks in 2023